Acurx Pharmaceuticals (ACXP) vs Creative Medical Technology (CELZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acurx Pharmaceuticals is the larger company by market cap ($6.9 million vs $6.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | CELZ |
|---|---|---|
| Share price | $1.24 | $0.82 |
| Market cap | $6.89M | $6.23M |
| 1-day change | -0.80% | -4.68% |
| EPS (TTM) | $-2.67 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $6.25 |
| 52-week low | $1.23 | $0.62 |
| Distance from 52-week high | -84.46% | -86.88% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1270.97% | +2339.02% |
| Average volume | 125.08K | 6.77M |
| Shares outstanding | 5.56M | 7.59M |
| Employees | 4 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4 employees
ACXP vs CELZ FAQ
Which is bigger, Acurx Pharmaceuticals or Creative Medical Technology?
Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.89M compared with $6.23M for Creative Medical Technology (CELZ).
Are Acurx Pharmaceuticals and Creative Medical Technology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Acurx Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Creative Medical Technology.